Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 199

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas

de Jonge, Marthe M., Auguste, Aurélie, van Wijk, Lise M., Schouten, Philip C., Meijers, Matty, ter Haar, Natalja T., Smit, Vincent T.H.B.M., Nout, Remi A., Glaire, Mark A., Church, David N., Vrieling, Harry, Job, Bastien, Boursin, Yannick, de Kroon, Cor D., Rouleau, Etienne, Leary, Alexandra, Vreeswijk, Maaike P.G., Bosse, Tjalling · 2019 · Clinical Cancer Research

Abstract

Purpose: The elevated levels of somatic copy-number alterations (SCNAs) in a subset of high-risk endometrial cancers are suggestive of defects in pathways governing genome integrity. We sought to assess the prevalence of homologous recombination deficiency (HRD) in endometrial cancers and its association with histopathologic and molecular characteristics. Experimental Design: Fresh tumor tissue was prospectively collected from 36 endometrial cancers, and functional HRD was examined by the ability of replicating tumor cells to accumulate RAD51 protein at DNA double-strand breaks (RAD51 foci) induced by ionizing radiation. Genomic alterations were determined by next-generation sequencing and array comparative genomic hybridization/SNP array. The prevalence of BRCA-associated genomic scars, a surrogate marker for HRD, was determined in the The Cancer Genome Atlas (TCGA) endometrial cancer cohort. Results: Most endometrial cancers included in the final analysis (n = 25) were of non-endometrioid (52%), grade 3 (60%) histology, and FIGO stage I (72%). HRD was observed in 24% (n = 6) of cases and was restricted to non-endometrioid endometrial cancers (NEEC), with 46% of NEECs being HRD compared with none of the endometrioid endometrial cancers (EEC, P = 0.014). All but 1 of the HRD cases harbored either a pathogenic BRCA1 variant or high somatic copy-number (SCN) losses of HR genes. Analysis of TCGA cases supported these results, with BRCA-associated genomic scars present in up to 48% (63/132) of NEEC versus 12% (37/312) of EEC (P < 0.001). Conclusions: HRD occurs in endometrial cancers and is largely restricted to non-endometrioid, TP53-mutant endometrial cancers. Evaluation of HRD may help select patients that could benefit from treatments targeting this defect, including platinum compounds and PARP inhibitors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-18-1443

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 199

Metadata

Authors
de Jonge, M. M., Auguste, A., van Wijk, L. M., Schouten, P. C., Meijers, M., ter Haar, N. T., Smit, V. T. H. B. M., Nout, R. A., Glaire, M. A., Church, D. N., Vrieling, H., Job, B., Boursin, Y., de Kroon, C. D., Rouleau, E., Leary, A., Vreeswijk, M. P. G., & Bosse, T.
Venue
Clinical Cancer Research
Published
2019-02-01
Volume
25
Issue
3
Pages
1087-1097
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2900109386
Cited by
199
References
4
FWCI
12.79
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-18-1443
The paper
de Jonge, M. M., Auguste, A., van Wijk, L. M., Schouten, P. C., Meijers, M., ter Haar, N. T., Smit, V. T. H. B. M., Nout, R. A., Glaire, M. A., Church, D. N., Vrieling, H., Job, B., Boursin, Y., de Kroon, C. D., Rouleau, E., Leary, A., Vreeswijk, M. P. G., & Bosse, T. (2019). Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-18-1443

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.